SCHEMBL16296996

SCHEMBL16296996

COc1ccc(C2=C(N)C(=O)c3ccccc3C2=O)cc1

nearest known ligand 0.88

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.88
TP53 P04637 4/20 0.88
NPC1 O15118 3/20 0.88
RAB9A P51151 3/20 0.88
SMN1; SMN2 Q16637 3/20 0.88
TSHR P16473 1/20 0.88
MEN1 O00255 5/20 0.61
KMT2A Q03164 5/20 0.61
FGFR1 P11362 1/20 0.60
SRC P12931 1/20 0.60
FGFR2 P21802 1/20 0.60
FGFR4 P22455 1/20 0.60
FGFR3 P22607 1/20 0.60
HSP90AA1 P07900 7/20 0.57
HSP90AB1 P08238 6/20 0.57
PTPN1 P18031 1/20 0.55
ALDH1A1 P00352 3/20 0.55
HTT P42858 3/20 0.55
LMNA P02545 2/20 0.55
NPSR1 Q6W5P4 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6346941 0.82 MAPT (0.74) MAPTTP53NPC1RAB9ASMN1; SMN2
SCHEMBL19625611 0.80 MAPT (0.58) MAPTTP53NPC1RAB9ASMN1; SMN2
SCHEMBL14773924 0.80 ME2 (0.74) MAPTTP53NPC1RAB9ASMN1; SMN2
SCHEMBL16297081 0.80 MAPT (0.56) MAPTTP53NPC1RAB9ASMN1; SMN2
SCHEMBL16303891 0.80 MAPT (0.57) MAPTTP53NPC1RAB9ASMN1; SMN2
SCHEMBL6297709 0.79 MAPT (0.56) MAPTTP53NPC1RAB9ASMN1; SMN2
SCHEMBL16745451 0.75 RAB9A (0.60) MAPTTP53NPC1RAB9ASMN1; SMN2
SCHEMBL144791 0.75 FGFR1 (1.00) MAPTTP53NPC1RAB9ASMN1; SMN2
SCHEMBL10424199 0.73 ME2 (0.69) MAPTTP53NPC1RAB9ASMN1; SMN2
SCHEMBL16296803 0.73 HSP90AA1 (1.00) MAPTMEN1KMT2AHSP90AA1HSP90AB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170334842-A1 INHIBITORS OF THE MITF MOLECULAR PATHWAY UNIVERSITY OF KANSAS 2017-11-23 US disclosed
US-20170334842-A1 INHIBITORS OF THE MITF MOLECULAR PATHWAY UNIVERSITY OF KANSAS 2017-11-23 US disclosed
US-20170334842-A1 INHIBITORS OF THE MITF MOLECULAR PATHWAY UNIVERSITY OF KANSAS 2017-11-23 US disclosed
US-9745261-B2 Inhibitors of the MITF molecular pathway THE GENERAL HOSPITAL CORPORATION (US) 2017-08-29 US disclosed
US-9745261-B2 Inhibitors of the MITF molecular pathway THE GENERAL HOSPITAL CORPORATION (US) 2017-08-29 US disclosed
US-9745261-B2 Inhibitors of the MITF molecular pathway THE GENERAL HOSPITAL CORPORATION (US) 2017-08-29 US disclosed
US-20160130222-A1 INHIBITORS OF THE MITF MOLECULAR PATHWAY THE BROAD INSTITUTE, INC. 2016-05-12 US disclosed
US-20160130222-A1 INHIBITORS OF THE MITF MOLECULAR PATHWAY THE BROAD INSTITUTE, INC. 2016-05-12 US disclosed
US-20160130222-A1 INHIBITORS OF THE MITF MOLECULAR PATHWAY THE BROAD INSTITUTE, INC. 2016-05-12 US disclosed
EP-3007688-A2 INHIBITORS OF THE MITF MOLECULAR PATHWAY The General Hospital Corporation (US) 2016-04-20 EP disclosed
WO-2014201016-A2 INHIBITORS OF THE MITF MOLECULAR PATHWAY THE GENERAL HOSPITAL CORPORATION (US) 2014-12-18 WO disclosed
WO-2014201016-A2 INHIBITORS OF THE MITF MOLECULAR PATHWAY THE GENERAL HOSPITAL CORPORATION (US) 2014-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160130222-A1 INHIBITORS OF THE MITF MOLECULAR PATHWAY MITF, TFEB, TYR MAPT 4100/4885TP53 85/4885NPC1 2581/4885
US-20170334842-A1 INHIBITORS OF THE MITF MOLECULAR PATHWAY MITF, TFEB, TYR MAPT 4092/4885TP53 82/4885NPC1 2867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.